Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
MAIA Biotechnology, Inc. MAIA
$2.46
-$0.09 (-3.53%)
На 17:51, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
36108635.00000000
-
week52high
9.64
-
week52low
2.12
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-1.76000000
-
Last Dividend
0.00000000
-
Next Earnings Date
24 мар 2023 г. в 16:00
Описание компании
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Smith Stan | A | 513564 | 227 | 26 янв 2023 г. |
| Smith Stan | A | 513337 | 9 | 25 янв 2023 г. |
| Luput Cristian | A | 278572 | 504 | 13 янв 2023 г. |
| Vitoc Vlad | A | 793121 | 1266 | 04 янв 2023 г. |
| Vitoc Vlad | A | 791855 | 2324 | 03 янв 2023 г. |
| Louie Ngar Yee | A | 4568 | 4568 | 30 дек 2022 г. |
| Smith Stan | A | 3807 | 3807 | 30 дек 2022 г. |
| CHAOUKI STEVEN M | A | 3045 | 3045 | 30 дек 2022 г. |
| Vlad Laurentiu | A | 3045 | 3045 | 30 дек 2022 г. |
| Luput Cristian | A | 3045 | 3045 | 30 дек 2022 г. |
Новостная лента
MAIA Biotechnology to Participate in Four Upcoming Investor Conferences
Business Wire
05 янв 2023 г. в 08:00
CHICAGO--( BUSINESS WIRE )--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”) announced today that the management team will participate in the four upcoming investor conferences as follows:
MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Business Wire
29 сент 2022 г. в 09:01
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that it will present the results of a study of the anticancer agent 6-thio-dG (THIO) in hepatocellular carcinoma (HCC) in vitro and in vivo models at the EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics. The symposium is taking place Oct. 26-28, 2022
MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022
Business Wire
06 сент 2022 г. в 08:00
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it will present the design of its ongoing THIO-101 trial at the European Society for Medical Oncology (ESMO) Congress 2022, being held from September 9th to 13th in Paris, France. THIO is a telomere-targeting agent currently in clinical development to evaluate its activity in non-small ce